JERAD DALTON: Open Payments
NPI 1306835418 · INDIANAPOLIS, IN. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,002 in 121 payments from 19 companies in 2025. Trend: 2023 $8,006 · 2024 $3,237 · 2025 $2,002
Food & beverage: $1,994Education: $8
| Company | Payments | Amount |
|---|---|---|
| Janssen Pharmaceuticals, Inc | 11 | $271 |
| Supernus Pharmaceuticals, Inc. | 21 | $250 |
| Otsuka America Pharmaceutical, Inc. | 14 | $236 |
| Vanda Pharmaceuticals Inc. | 7 | $191 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 13 | $184 |
| Axsome Therapeutics, Inc. | 10 | $161 |
| Collegium Pharmaceutical, Inc. | 16 | $160 |
| Corium, LLC | 8 | $105 |
| Noven Therapeutics, LLC | 5 | $92 |
| Neurocrine BioSciences, Inc. | 3 | $65 |
Products named: SPRAVATO, Qelbree, REXULTI, HETLIOZ, CAPLYTA, Jornay PM, Auvelity, Azstarys.
Industry payments across IN — which companies pay providers there.
